Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jefferies has initiated Krystal Biotech at buy citing growth in sales of Vyjuvek (beremagene geperpavec), a gene therapy for ...
Arizona State Retirement System boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 8.5% in the 4th ...
The leading integrated facility management services provider informed the stock exchanges in a filing that the Ministry of ...
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the ...
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
The new agreements, which include contracts at Chennai International Airport in Tamil Nadu, Trivandrum International Airport ...
Shares of Krystal Biotech KRYS have gained 15.8% in the past month compared with the industry’s growth of 4%. The stock has also outperformed the industry and the sector in this timeframe.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback